Calithera Biosciences Inc (CALA.OQ)
CALA.OQ on NASDAQ Stock Exchange Global Select Market
5.90USD
24 Apr 2018
5.90USD
24 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$5.90
$5.90
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
109,416
109,416
52-wk High
$20.00
$20.00
52-wk Low
$5.38
$5.38
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 7.25 | -0.308 |
| Sep '17 | 7.25 | -0.171 | |
| Jun '17 | 7.26 | -0.147 | |
| Mar '17 | 4.19 | -0.221 | |
| FY 2016 | Dec '16 | 0.00 | -0.452 |
| Sep '16 | 0.00 | -0.438 | |
| Jun '16 | 0.00 | -0.546 | |
| Mar '16 | 0.00 | -0.521 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 7.19 | 7.30 | 6.90 | 6.90 |
| Quarter Ending Sep-18 | 4 | 7.19 | 7.30 | 6.90 | 6.90 |
| Year Ending Dec-18 | 4 | 28.62 | 29.20 | 28.00 | 18.35 |
| Year Ending Dec-19 | 4 | 14.42 | 28.00 | 2.77 | 110.30 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 5 | -0.30 | -0.21 | -0.36 | -0.13 |
| Quarter Ending Sep-18 | 5 | -0.31 | -0.21 | -0.37 | -0.13 |
| Year Ending Dec-18 | 5 | -1.24 | -0.84 | -1.46 | -1.14 |
| Year Ending Dec-19 | 5 | -1.88 | -1.01 | -2.89 | 0.36 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 84.02 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 293.16 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 91.58 | 24.22 | |
| Beta | -- | 0.90 | 0.88 | |
| Price to Sales (TTM) | 53.46 | 110.88 | 5.71 | |
| Price to Book (MRQ) | 3.76 | 13.58 | 5.37 | |
| Price to Tangible Book (MRQ) | 3.77 | 14.04 | 6.95 | |
| Price to Cash Flow (TTM) | -- | 71.40 | 23.32 | |
| % Owned Institutions | 90.00 | 12.75 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.31 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 0.26 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 1.66 | 5.32 | |
| Payout Ratio(TTM) | -- | 15.71 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 399.06 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 78.82 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -- | 32.16 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 73.06 | 25.00 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 37.17 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 38.99 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 40.29 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.80 | 2.19 |
| Current Ratio (MRQ) | 4.95 | 5.30 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 22.96 | 12.18 |
| Total Debt to Equity (MRQ) | 0.00 | 24.62 | 16.45 |
| Interest Coverage (TTM) | -- | -99.34 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 40.02 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 51.13 | 52.20 | |
| EBITD Margin (TTM) | -256.99 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -574.72 | 10.96 | |
| Operating Margin (TTM) | -259.69 | -718.49 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -- | -596.03 | 6.40 | |
| Pre-Tax Margin (TTM) | -251.99 | -692.96 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -599.39 | 6.81 | |
| Net Profit Margin (TTM) | -251.99 | -694.19 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -602.24 | 3.09 | |
| Effective Tax Rate (TTM) | -- | 22.62 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.21 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 228,940 | 22,625,667 | 846,830,423 | |
| Net Income/Employee (TTM) | -576,900 | 2,971,219 | 99,616,130 | |
| Receivable Turnover (TTM) | -- | 20.16 | 5.78 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.35 | |
| Asset Turnover (TTM) | 0.08 | 0.39 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -20.80 | -1.11 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -- | -0.57 | 12.31 | |
| Return on Investment (TTM) | -24.22 | 1.58 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -- | 2.21 | 16.10 | |
| Return on Equity (TTM) | -26.14 | 2.41 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -- | 3.09 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -7.81 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Calithera Biosciences Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 6.15 | 2.49 | 62 | 53 |
| 13 Week | -3.63 | -8.32 | 44 | 65 |
| 26 Week | 53.33 | 41.68 | 85 | 77 |
| 52 Week | 429.14 | 348.49 | 98 | 50 |
| YTD | 430.77 | 366.12 | 99 | 58 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma
- BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln
- BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018
- BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
- BRIEF-Calithera Biosciences Q3 operating loss per share $0.17
Institutional Holders
| % Shares Owned: | 82.53% |
| # of Holders: | 152 |
| Total Shares Held: | 29,584,218 |
| 3 Mo. Net Change: | 130,354 |
| # New Positions: | 0 |
| # Closed Positions: | 2 |
| # Increased Positions: | 9 |
| # Reduced Positions: | 6 |
| # Net Buyers: | 3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.